Gain of Chromosomal Region 3q26 as a Prognostic Biomarker for High-Grade Cervical Intraepithelial Neoplasia: Literature Overview and Pilot Study.
3q26
Biomarker
Cervical intraepithelal neoplasia
Prognosis
hTERC
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
18
08
2018
accepted:
04
10
2018
pubmed:
27
10
2018
medline:
14
6
2019
entrez:
27
10
2018
Statut:
ppublish
Résumé
Approximately 20-40% of high-grade Cervical Intraepithelial Neoplasia (CIN) regresses spontaneously, but the natural prognosis of an individual lesion is unpredictable. Gain of the chromosomal 3q region, which contains the human telomerase RNA gene on 3q26, is found in CIN lesions and cervical carcinoma and shows correlation with disease grade. The aim of this study is to assess whether 3q26 gain as a single genetic marker can predict the natural prognosis of high-grade CIN, by performing a review of the literature and pilot study. A literature review was conducted. Additionally, we performed a pilot study in 19 patients with histologically confirmed high-grade CIN lesions who were followed for a mean of 115 days, after which loop excision was performed. Fluorescent in situ hybridization analysis was performed on the initial diagnostic biopsies to determine gain of 3q26. Eight studies were included in the literature overview, with a total of 407 patients. Of these, only 22 patients had high-grade lesions. All studies found an association between 3q26 gain and disease prognosis. Positive predictive values (PPV) ranged from 50 to 93%, negative predictive values (NPV) ranged from 75 to 100%. Only five out of 155 patients (3.2%) without 3q26 gain showed disease persistence or progression. In our pilot study on 3q26 gain in high-grade CIN, the PPV of 3q26 gain for disease persistence was 67%, the NPV 100%. All four patients without 3q26 gain showed disease regression. In conclusion, the absence of 3q26 gain in diagnostic biopsies may be applied to identify high-grade CIN lesions with a high probability of disease regression.
Identifiants
pubmed: 30361910
doi: 10.1007/s12253-018-0480-y
pii: 10.1007/s12253-018-0480-y
pmc: PMC6449281
doi:
Substances chimiques
Biomarkers, Tumor
0
Genetic Markers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
549-557Références
J Natl Cancer Inst. 2000 May 3;92(9):690-8
pubmed: 10793105
Am J Pathol. 2005 Apr;166(4):1229-38
pubmed: 15793301
Clin Cancer Res. 2005 Jul 1;11(13):4717-23
pubmed: 16000566
Carcinogenesis. 2006 Feb;27(2):337-43
pubmed: 16123119
J Pathol. 2006 Dec;210(4):412-9
pubmed: 17054308
Lancet Oncol. 2008 May;9(5):425-34
pubmed: 18407790
Mod Pathol. 1991 Jul;4(4):503-13
pubmed: 1924281
Gynecol Oncol. 2009 Jul;114(1):80-3
pubmed: 19394683
Hum Pathol. 2009 Oct;40(10):1474-8
pubmed: 19540557
Am J Obstet Gynecol. 2010 Jun;202(6):581.e1-5
pubmed: 20171606
Nat Rev Cancer. 2010 Aug;10(8):550-60
pubmed: 20592731
J Clin Pathol. 2011 Apr;64(4):303-7
pubmed: 21421698
Int J Cancer. 2012 May 15;130(10):2438-44
pubmed: 21702034
Clin Microbiol Rev. 2012 Apr;25(2):215-22
pubmed: 22491770
Int J Gynecol Cancer. 2012 Jun;22(5):742-7
pubmed: 22635026
Chin Med J (Engl). 2012 May;125(9):1599-602
pubmed: 22800828
Obstet Gynecol. 2012 Jul;120(1):152-9
pubmed: 22914404
Gynecol Oncol. 2012 Dec;127(3):489-94
pubmed: 23017821
Cancer Cytopathol. 2013 Aug;121(8):423-31
pubmed: 23408758
Expert Opin Med Diagn. 2013 Jul;7(4):365-77
pubmed: 23777477
Eur J Cancer. 2014 Jan;50(1):85-98
pubmed: 24054023
J Low Genit Tract Dis. 2014 Jul;18(3):218-27
pubmed: 24477173
Eur J Gynaecol Oncol. 2014;35(3):289-91
pubmed: 24984543
Am J Obstet Gynecol. 2015 Jul;213(1):51.e1-51.e8
pubmed: 25659466
Expert Rev Mol Diagn. 2015 Apr;15(4):527-46
pubmed: 25703310
J Low Genit Tract Dis. 2017 Jan;21(1):42-46
pubmed: 27611439
Cytometry. 1995 Jul 1;20(3):193-202
pubmed: 7587704